Navigation Links
Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
Date:1/17/2008

SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the receipt of a $2.1 million cash payment from AnGes MG, Inc. for costs associated with the ongoing Allovectin-7(R) Immunotherapeutic for Metastatic Melanoma (AIMM) Phase 3 trial.

AnGes is funding the Phase 3 pivotal trial of Allovectin-7(R) under a previously announced collaborative agreement through a scheduled series of cash payments and equity investments totaling $22.6 million, for which AnGes received exclusive marketing rights in Japan and other key Asian countries, and also will receive certain royalties for sales in the United States and European countries. Vical is conducting the trial in accordance with a Special Protocol Assessment (SPA) completed with the U.S. Food and Drug Administration (FDA).

The payment was triggered by utilization of previous cash balances, reflecting progress in the trial. The cash payment was received as anticipated in late December, and will be included in Vical's year-end 2007 cash balances, consistent with the company's guidance of a projected 2007 net cash burn of $27 million to $32 million. Revenue related to the cash payment will be deferred and matched to trial expenses as they are incurred.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
2. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
3. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
4. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014   Taiho ... Co., Ltd. ( Japan ), announced ... granted Fast Track designation for TAS-102 (nonproprietary names: ... drug under investigation for the treatment of refractory ... has initiated a rolling NDA submission to the ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis Alliance ... (HNF), both philanthropies, announced today the creation of ... the treatment of the rare disease known as ... announced its alliance model earlier this month. Today,s ... of a collaborative model where researchers and all ...
(Date:10/18/2014)... , Oct. 18, 2014  In a ... Rights Campaign (HRC), the nation,s largest lesbian, gay, ... endorsed the use of Truvada for Pre-Exposure Prophylaxis ... tool used to prevent the spread of a ... the only brand name anti-HIV drug combination currently ...
Breaking Medicine Technology:Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... announces that a new market research report is ... Global Overview of Herbal/Traditional Products ... for "safer and natural" options remains strong in ... of traditional medicine, consumers are increasing their purchases ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), today announced ... preferred Tier 2 formulary status with CVS Caremark ... and Part D Drug Lists), two of the ... million Americans.(1) The U.S. Food and Drug Administration ...
Cached Medicine Technology:Reportlinker Adds A Global Overview of Herbal/Traditional Products 2Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers 2Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers 3Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers 4Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers 5
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... of about 20% of the women who have attained the childbearing ... across the US involving several thousand women. //In the case of ... women belonging to the 16 years to 49 years age group, ... ,The Illinois Chapter of the Sierra Club’s Jack Darin has termed ...
... manufacturer of the experimental AIDS drug GS 9137 Gilead Sciences ... were successful, as lower levels of HIV were noticed in ... The experiment was conducted over a period of 10 days ... were also not seen to be of a serious nature. ...
... Agency for Healthcare Research and Quality has reported that more ... treat burn victims is billed to Medicare or Medicaid, government ... ,According to statistics, the average charge is $59,600 ... the average charge for burn victims with private insurance ...
... :When you doodle for a cause, then it is art ... rub shoulders with the Who’s Who clan, to name a ... their mite for the third National Doodle Day on March ... for the Epilepsy Action and The Neurofibromatosis Association, and is ...
... lives in a competitive world, according to a recent ... educational achievements are concerned, // there is not much ... with a normal birth weight. Earlier research suggested premature ... and academic achievement. ,The researchers studied ...
... following use of the drug aprotinin, marketed as Trasylol, ... drug in heart surgery patients.// The clotting drug is ... cardiac surgery. ,It has now been found ... twice as likely to develop kidney failure and suffer ...
Cached Medicine News:Health News:Art Attack: Doodling For a Cause! 2Health News:Safety Of Heart Drug Questioned 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
Medicine Products: